Abstract: A method of identifying the presence or absence of an infected state in the living body by obtaining a biological fluid sample from a living body, adding to the sample a material known to bind with immune complex, adding to samples of the resulting material labelled reagents known to react specifically with antigen portions of different immune complexes, separating excess of the reagents and detecting the presence or absence of the label in the residual mixtures thereby to identify the nature of any reacted antigen portion of immune complex therein.

Abstract: A novel method for detecting tumor associated antigen in patient's serum or plasma samples is provided. Tumor associated antigen in the form of immune complexes is detected by first applying the patient's serum sample to an immunoadsorbent column to enrich the amount of immune complexes relative to other serum components. The amount of tumor associated antigen is then detected in the enriched sample in a solid-phase assay employing a solid-phase receptor for the immune complexes and a labelling system specific for the tumor associated antigen.

Abstract: A method is disclosed for the production of antibodies to haptens which comprises binding the hapten to an antibody from one species, injecting the antibody-hapten into another species, and isolating the antibodies produced in response to the hapten.

Abstract: A procedure for detecting malignancy includes culturing human colon tumor cells in a capillary system. A rabbit is immunized with byproducts of the culture. An antibody produced in the rabbit is labeled with .sup.125 I using lactoperoxidase according to a known method. Blood samples are drawn from a being to be tested. The drawn blood is processed to produce serum. The immune complexes are removed from the serum with purified protein A from the Staphlococcus Aureus Cowan strain. The removed immunocomplexes are dissociated with 0.2M glycene/HCl pH 2.8. The labeled antibody is combined with the antigen component of the immunocomplex to produce a new labeled immunocomplex. The newly formed immunocomplex is precipitated with PEG 6000. The newly formed labeled immunocomplexes are counted in a gamma auto counter.

Abstract: The in-vivo effectiveness of cytostatic agents against immunological active tumors is determined by measuring immune markers and/or immune parameters in the serum before and up to 3 days after the application of the cytostatic agent. Preferably the deviation of coomplement binding capacity is used as immune parameter.

Abstract: An immunoassay of a specimen of a serum or the like to determine the composition of immune complexes, includes producing on a plastic base a layer of a non-proteinaceous, non-ionic polymer which will adhere to the plastic base and has the capability of adsorbing immune complexes of the specimen, placing a specimen on the layer and treating the layer to produce an indication of the composition of the immune complexes. The polymer may be polyethylene glycol, dextran, polyvinyl chloride, a polymeric polyol or an adduct of polyethylene glycol or mixtures thereof. Washing with conventional solutions, addition of monoclonal and/or polyclonal antibodies coupled with an enzyme and addition of a substrate reactive therewith to determine the antigen component, are similar to the ELISA test, with color measurement as by spectrophotometer. Or, the addition of anti IgG-I.sup.125 and measurement by a scintillation counter may be used. Addition of IgG, IgA, IgE, IgG.sub.

Abstract: A murine monoclonal antibody combining site produced by a hybridoma formed by fusion of cells from a myeloma cell line and lymphocytes that produce antibodies that react (1) with isolated human C3b receptor and (2) with C3b receptor-bearing cells from a mammal immunized with human C3b receptor is disclosed.

Abstract: An immunoassay utilizing a novel liposome composition in which there is incorporated a stabilizing or destabilizing component and an antigen. The presence of cognate antibodies in test samples is detected by the alteration of the supramolecular structure of the liposomes resulting in changes in stabilization. Destabilization can be detected, and in certain cases, caused by, the addition of magnesium or calcium ions. Increased stabilization can be detected by the polymerization of bilayer components in response to ultraviolet light. Antibody-antigen interactions at the liposome surface mediate the stabilization/destabilization response.

Abstract: A method for the rapid separation of Dirofilaria immitis immune complexes in a sample of blood or bodily fluid from an animal infected with Dirofilaria immitis preparatory to assaying for the presence of circulating parasite antigens of Dirofilaria immitis involves the steps of (a) lowering the pH of the sample to below 3.0 to effect the separation of circulating parasite antigens of Dirofilaria immitis from antibodies therefor in the sample; (b) heating the sample to a temperature within the range of approximately 56.degree. C. to 90.degree. C. for a sufficient period of time to denature the separated antibodies; and (c) increasing the pH of the resulting sample to within the range of approximately 7 to 8 to produce a sample which may be assayed for the presence of circulating parasite antigens of Dirofilaria immitis without interference from the separated antibodies.

Abstract: A method for assaying circulating immune complexes comprisescontacting the circulating immune complexes in solution in serum with a staphylococcal protein-A linked to a detectable label, whereby a CIC-protein-A-label complex is formed,selectively precipitating the CIC-SPA-label complex by contacting the complex with polyethylene glycol,separating the precipitated CIC-SPA-label complex from the serum,measuring the quantity of the label in the precipitated CIC-protein-A-label complexcomparing the measured quantity of label with at least one standard prepared by subjecting a solution containing a known amount of CIC or functional equivalent material to the same assay. The method requires only a single precipitation step and in a preferred embodiment the formation of the CIC-SPA-label complex may be formed in a single step.

Abstract: A composition having a protein binding solid support onto which is bound a mixture of antigens and antibodies which are both bound to the solid support individually and are not present in the form of an immune complex.

Abstract: Method and test kit for detecting Clq-containing complexes in human serum containing native serum Cl. The method uses a monoclonal antibody which selectively reacts with human Clq in the presence of native human serum Cl. Preparation of hybridomas generating such antibodies is also disclosed. The method is applicable to detection of autoimmune diseases and AIDS.

Abstract: Monoclonal antibody reactive with SCC cells and unreactive with human neuroblastoma cells, human squamous cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells.

Abstract: An assay for detecting SLE antibodies utilizing a novel liposome composition in which there is entrapped a divalent cation responsive indicator. The presence of such antibodies is detected by their stabilization of the supermolecular structure of the liposomes. Such stabilization can be detected, and in certain cases, caused by, the addition of magnesium or calcium ions.

Abstract: A process and apparatus for removing immuno-specifically recognizable substances in the form of immune complexes from a solution. The solution containing preformed immune complexes or immune complexes already present therein is contacted with an adsorbent consisting of non-immunospecific factor such as Clq, rheumatoid factor, Fc receptor and Fc receptor-bearing cells.

Abstract: A monoclonal antibody which specifically binds to the surface recognition structure of a predetermined mature human T cell clone, which recognition structure renders the clone capable of acting as causative agent in a predetermined autoimmune disease, the monoclonal antibody being capable of specifically binding to the recognition structure of the clone to inhibit the ability of the clone to act as a causative agent in the predetermined autoimmune disease.

Abstract: A method of diagnosis using an attached material for binding to an immune complex, by treating the bound complex with a series of different reagents or mixtures thereof and detecting the presence or absence of reaction in each case, this method being based on immune complexes produced in the body during infection and allowing much earlier detection and diagnosis of infection thereby providing the facility for treatment to reduce the damage caused to the body by the formation of complex.

Abstract: A suspension of particles such as carboxylated polystyrene latex particles are coated (as by carbodiimide coupling) with an antigen (such as chemically modified Bovine Serum Albumin). The antigen-coated particles are incubated with a gamma-globulin to the antigen (such as can be produced by immunizing rabbits) under non-agglutinating conditions. The particles having antigen/gamma-globulin immune complexes are recovered and resuspended to form a diagnostic reagent which agglutinates when mixed with human serum containing Rheumatoid Factor.

Abstract: An antibody is obtained by using as an antigen a complex of an antigen and the F(ab').sub.2 fragment of the human antibody of this antigen or an aggregate of the F(ab').sub.2 fragment of human immunoglobulin. This antibody reacts with an immune complex in a blood serum of a patient of systemic lupus erythematosus and with an immune complex in a blood serum of a patient of rheumatoid arthritis, and it does not react with an aggregated IgG. The amount of immune complex in a blood serum is easily and exactly determined by using this antibody.

Abstract: A process for the detection and for the determination of immunocomplexes in liquids is described. It is based on determining the rate at which the immunoglobulin or the antigen present in the complex reacts with an appropriate immuno-partner, and relating this rate to the rate at which this immunoglobulin or antigen reacts with the corresponding immuno-partner in an immunocomplex-free liquid.

Abstract: A method for analyzing cells to determine whether they have substantial numbers of H1 and H2 histamine receptors. Also an assay kit and a composition for conducting such analyses. The assays involve fluorescent polymeric molecules to which a plurality, preferably from about 30 to about 100, of histamine or histamine blocker molecules are attached. Procedures for optimizing several variables which are essential to effective and reliable determinations.

Abstract: A process for determining the presence of an antigen or antibody in a sample wherein said antigen or antibody exists in the form of an immune complex which comprises:A. contacting the immune complex originating from the sample suspected of containing immune complex with a dissociating buffer whereby said immune complex, if present, is dissociated into antigen and antibody;B. contacting a solid support which binds proteins with said dissociating buffer suspected of containing antigen or antibody and removing said buffer;C. washing said solid support;D. adding protein to fill unoccupied sites on said solid support;E. adding radioactively labeled or enzyme labeled antibody or antigen to said solid support, said labeled antibody or antigen corresponding to antigen or antibody on said solid support, incubating the resultant mass and washing the same;F. measuring the radioactivity or enzymatic activity associated with the solid support.

Abstract: An immunoassay of a specimen of a serum or the like to determine immune complexes, includes producing on a plastic base a layer of a non-proteinaceous, non-ionic polymer which will adhere to the plastic base and has the capability of absorbing immune complexes of the specimen, placing a specimen on the layer and treating the layer to produce an indication of the amount of immune complexes. The polymer may be polyethylene glycol, dextran, polyvinyl chloride, a polymeric polyol or an adduct of polyethylene glycol. Washing with conventional solutions, addition of an antihuman IgG coupled with an enzyme and addition of a substrate reactive therewith, are similar to the ELISA test, with color measurement as by spectrophotometer. Or, the addition of anti IgG-I.sup.125 and measurement by a scintillation counter may be used. The ethylene glycol may range in molecular weight from 2,000 to 20,000, although 6,000 to 8,000 is preferred.

Abstract: Method for detecting circulating immune complexes containing endogenously bound Clq. Capillary tubes are filled with a mixture of Clq coated GPO reagent cells, rabbit anti-Clq antibodies, and precipitate from the biological fluid sample containing immune complexes. The mixture is allowed to react and the tubes read for the presence or absence of agglutination indicative of the absence or presence of said immune complexes respectively.

Abstract: Kit for detecting circulating immune complexes containing endogenously bound Clq. Capillary tubes are filled with a mixture of Clq coated GPO reagent cells, rabbit anti-Clq antibodies, and precipitate from the biological fluid sample containing immune complexes. The mixture is allowed to react and the tubes read for the presence or absence of agglutination indicative of the absence or presence of said immune complexes respectively.